Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
Agency: National Institutes of Health
- 93.350 -- National Center for Advancing Translational Sciences
Forecasted opportunityLast Updated: May 13, 2026
Important dates
- Forecasted post date: January 16, 2026
- Forecasted application due date: June 16, 2026
- Forecasted award date: April 15, 2027
- Forecasted project start date: April 15, 2027
- Fiscal Year: 2027
Award details
- Expected project funding: $1,600,000
- Expected awards: 2
Award min.
Not specified
Award max.
Not specified
- Funding opportunity number:RFA-TR-25-016
- Cost sharing or matching requirement:No
- Funding instrument type:
- Cooperative agreement
- Opportunity Category:Discretionary
- Opportunity Category Explanation:Not specified
- Category of Funding Activity:
- Health
- Category Explanation:Not specified
History
- Forecast posted date: September 29, 2025
- Archive date: Not specified
- Version: 1
Summary
NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that will develop, validate and demonstrate the utility of advanced 3-D tissue models for testing the efficacy of various therapeutic modalities, including small molecules and biologics and accelerate the discovery and development of new therapeutics across different diseases.
The initiative will develop advanced 3-D drug screening models adaptable to high throughput assays. These non-animal models are expected to mimic structural, biochemical and mechanical properties of tissue that are representative of a drug’s behavior in a body, resulting in improved predictive accuracy. This is an expansion upon the work conducted under previous NOFOs, RFA-TR-17-007, RFA-TR-19-020 and RFA-TR-21-015, that have focused on development of 3-D skin and other tissue models for drug screening. The applicants are required to utilize the 3-D modeling/drug screening expertise and infrastructure available at the NCATS 3-D Bioprinting laboratory. 3-D tissue models in a well-based drug screening platform should be as complex as necessary to achieve physiological/pharmacological relevance, and as simple as possible to make the models robust, reliable and amenable to drug screening. Grant authorities that allow NCATS to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.
Eligibility
Government
- City or township governments
- County governments
- State governments
- Special district governments
- Public and Indian housing authorities
- Federally recognized Native American tribal governments
Nonprofit
- Nonprofits non-higher education with 501(c)(3)
- Nonprofits non-higher education without 501(c)(3)
- Other Native American tribal organizations
Business
- Small businesses
- For-profit organizations other than small businesses
Education
- Independent school districts
- Private institutions of higher education
- Public and state institutions of higher education
Miscellaneous
- Other
Additional information on eligibility
Documents
No documents are currently available.
Agency contact information
Email: dobrila.rudnicki@nih.gov
dobrila.rudnicki@nih.gov
Link to additional information
No additional information is available
